CU20160048A7 - Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio - Google Patents

Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio

Info

Publication number
CU20160048A7
CU20160048A7 CUP2016000048A CU20160048A CU20160048A7 CU 20160048 A7 CU20160048 A7 CU 20160048A7 CU P2016000048 A CUP2016000048 A CU P2016000048A CU 20160048 A CU20160048 A CU 20160048A CU 20160048 A7 CU20160048 A7 CU 20160048A7
Authority
CU
Cuba
Prior art keywords
morfolin
pirimidin
pirazol
olato
triazol
Prior art date
Application number
CUP2016000048A
Other languages
English (en)
Other versions
CU24515B1 (es
Inventor
Heike Neumann
Klaus Benke
Michael Formell
Gabriele Winter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160048(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20160048A7 publication Critical patent/CU20160048A7/es
Publication of CU24515B1 publication Critical patent/CU24515B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con formas sólidas de dosificación farmacéutica para administración oral que comprenden 1-[6-(MORFOLIN-4-IL)PIRIMIDIN-4-IL]-4-(1H-1,2,3-TRIAZOL-1-IL)-1H-PIRAZOL-5-OLATO DE SODIO caracterizadas porque el ingrediente activo (I) se Iibera, y también métodos para Ia preparación de las mismas, uso de las mismas como medicamentos, y también el uso de las mismas para profilaxis, profilaxis secundaria o el tratamiento de trastornos, particularmente trastornos cardiovasculares, fallo cardiaco, anemia, trastornos renales crónicos e insuficiencia renal.
CU2016000048A 2013-10-17 2014-10-13 Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio CU24515B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13189145 2013-10-17
PCT/EP2014/071855 WO2015055564A1 (de) 2013-10-17 2014-10-13 Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat

Publications (2)

Publication Number Publication Date
CU20160048A7 true CU20160048A7 (es) 2016-10-28
CU24515B1 CU24515B1 (es) 2021-05-12

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000048A CU24515B1 (es) 2013-10-17 2014-10-13 Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio

Country Status (35)

Country Link
US (1) US9827198B2 (es)
EP (1) EP3057580B1 (es)
JP (1) JP6525979B2 (es)
KR (1) KR102330953B1 (es)
CN (1) CN105636580B (es)
AP (1) AP2016009135A0 (es)
AR (1) AR098064A1 (es)
AU (1) AU2014336389B2 (es)
BR (1) BR112016007588A2 (es)
CA (1) CA2927437C (es)
CL (1) CL2016000857A1 (es)
CU (1) CU24515B1 (es)
DK (1) DK3057580T3 (es)
DO (1) DOP2016000078A (es)
EA (1) EA032932B1 (es)
ES (1) ES2868228T3 (es)
GT (1) GT201600072A (es)
HR (1) HRP20210691T1 (es)
HU (1) HUE054107T2 (es)
IL (1) IL244933B (es)
JO (1) JO3645B1 (es)
LT (1) LT3057580T (es)
MA (1) MA38974B2 (es)
MX (1) MX2016004628A (es)
MY (1) MY190202A (es)
NI (1) NI201600054A (es)
PE (1) PE20160669A1 (es)
PH (1) PH12016500716B1 (es)
SA (1) SA516370940B1 (es)
SI (1) SI3057580T1 (es)
TN (1) TN2016000135A1 (es)
TW (1) TWI746418B (es)
UA (1) UA119855C2 (es)
UY (1) UY35784A (es)
WO (1) WO2015055564A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7355020B2 (ja) * 2018-08-31 2023-10-03 アステラス製薬株式会社 経口投与用医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
KR20090119993A (ko) * 2007-03-13 2009-11-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 구강내 붕괴정
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
PH12016500716A1 (en) 2016-06-20
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
WO2015055564A1 (de) 2015-04-23
LT3057580T (lt) 2021-04-12
DK3057580T3 (da) 2021-05-10
MA38974B2 (fr) 2020-11-30
MX2016004628A (es) 2016-08-01
BR112016007588A2 (pt) 2017-09-12
EA201690788A1 (ru) 2016-09-30
EP3057580A1 (de) 2016-08-24
JO3645B1 (ar) 2020-08-27
HUE054107T2 (hu) 2021-08-30
NI201600054A (es) 2016-09-21
TWI746418B (zh) 2021-11-21
CL2016000857A1 (es) 2016-11-25
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27
CA2927437A1 (en) 2015-04-23
KR20160068784A (ko) 2016-06-15
DOP2016000078A (es) 2016-08-15
KR102330953B1 (ko) 2021-11-26
IL244933A0 (en) 2016-05-31
CA2927437C (en) 2022-06-28
ES2868228T3 (es) 2021-10-21
TN2016000135A1 (en) 2017-10-06
SI3057580T1 (sl) 2021-07-30
PE20160669A1 (es) 2016-08-04
JP2016538256A (ja) 2016-12-08
AU2014336389A1 (en) 2016-05-12
US9827198B2 (en) 2017-11-28
AU2014336389B2 (en) 2020-01-30
GT201600072A (es) 2018-12-19
UY35784A (es) 2015-05-29
EP3057580B1 (de) 2021-02-24
TW201607568A (zh) 2016-03-01
NZ718063A (en) 2021-06-25
CU24515B1 (es) 2021-05-12
US20160256394A1 (en) 2016-09-08
MY190202A (en) 2022-04-04
PH12016500716B1 (en) 2016-06-20
HRP20210691T1 (hr) 2021-06-11
MA38974A1 (fr) 2017-05-31
JP6525979B2 (ja) 2019-06-05
CN105636580A (zh) 2016-06-01
CN105636580B (zh) 2020-03-31
IL244933B (en) 2020-11-30
EA032932B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MX2013003635A (es) Compuestos de n-heteroarilo.
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
DOP2016000078A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
BR112017014295A2 (pt) composição farmacêutica.
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
MX383685B (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.